Vanguard Health Care Fund Admiral Shares Price & Performance (VGHAX)

HCW Biologics has completed a $5 million equity raise with an institutional investor, aiming to open new clinical sites for its Phase 1 trial of HCW9302 in autoimmune disorders. The company plans to intensify business development in late 2025, seeking partners to commercialize its immune-cell engager technology.1

The Vanguard Capital Opportunity Fund Admiral Shares closed at $189.40 on May 15, 2025, maintaining stability despite recent market volatility. The fund’s consistent pricing this week reflects resilience, even as broader equity markets have experienced swings due to shifting trade and economic sentiment.23

Sensus Healthcare reported a Q1 net loss of $2.6 million, missing EPS forecasts, while revenue surpassed expectations at $8.3 million. Despite the earnings miss, management remains optimistic about returning to profitability in 2025, planning to expand customer agreements and awaiting FDA feedback on its Transdermal Infusion system.4